$SCYX SEC Filings

Filed On	Filing
28 Sep 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need
22 Sep 2026	Form 4: Burke Steven Keith, Director Received 5,750 shares as a grant or award · Granted 5,750 Stock Option (Right to Buy)
22 Sep 2026	Form 3: Burke Steven Keith, Director No securities owned
22 Sep 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure JERSEY CITY, N.J., September 22, 2026 – SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appoint...
11 Sep 2026	Form 4: Subramanian Sanjay, Chief Financial Officer Granted 100,000 Stock Option (Right to Buy)
11 Sep 2026	Form 3: Subramanian Sanjay, Chief Financial Officer No securities owned
10 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation; Other Events Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies.
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
12 Aug 2026	SCHEDULE 13G
10 Aug 2026	S-8
10 Aug 2026	10-Q
20 Jul 2026	SCHEDULE 13G/A
08 Jul 2026	SCHEDULE 13G/A
30 Jun 2026	Form 4: Tinmouth Brian Philippe, Director Received 2,875 shares as a grant or award · Granted 2,875 Stock Option (Right to Buy)
30 Jun 2026	Form 4: Macdonald Guy, Director Received 2,875 shares as a grant or award · Granted 2,875 Stock Option (Right to Buy)
30 Jun 2026	Form 4: Anido Armando, Director Received 2,875 shares as a grant or award · Granted 2,875 Stock Option (Right to Buy)
30 Jun 2026	Form 4: Hastings David C, Director Received 2,875 shares as a grant or award · Granted 2,875 Stock Option (Right to Buy)
30 Jun 2026	Form 4: Hanham Ann, Director Received 2,875 shares as a grant or award · Granted 2,875 Stock Option (Right to Buy)
26 Jun 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders +1 more

Comments